Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis
Several drugs in development for nonalcoholic fatty liver disease (NAFLD) aim to decrease the amount of fat in the liver. We compared quantity and quality of fat in subcutaneous, visceral and muscle compartments, liver fibrosis, and prevalence of metabolic abnormalities between Chinese patients with...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2019-12-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1435 |
| _version_ | 1797761785252544512 |
|---|---|
| author | Wei Zhang Rui Huang Yi Wang Huiying Rao Lai Wei Grace L. Su Anna S. Lok |
| author_facet | Wei Zhang Rui Huang Yi Wang Huiying Rao Lai Wei Grace L. Su Anna S. Lok |
| author_sort | Wei Zhang |
| collection | DOAJ |
| description | Several drugs in development for nonalcoholic fatty liver disease (NAFLD) aim to decrease the amount of fat in the liver. We compared quantity and quality of fat in subcutaneous, visceral and muscle compartments, liver fibrosis, and prevalence of metabolic abnormalities between Chinese patients with moderate/severe hepatic steatosis versus those with mild hepatic steatosis. NAFLD patients were prospectively recruited from Peking University People's Hospital in Beijing, China. All patients had baseline body composition measurements using computed tomography and analytic morphomics, clinical evaluation, labs and Fibroscan® controlled attenuation parameter and liver stiffness measurement. Moderate/severe hepatic steatosis was defined as computed tomography liver attenuation of 40 Hounsfield units or less. Calorie intake and physical activity were based on self‐report. A total of 160 NAFLD patients were included (46% men, median age 47 years): 50% had normal body mass index (BMI), 24% were diabetic, and 56% had metabolic syndrome (MS). Fifty‐three (33%) had moderate/severe steatosis, of whom 19 (35.8%) had normal BMI, and the rest had mild steatosis. Patients who had moderate/severe steatosis had significantly higher BMI, waist circumference, aminotransferases, controlled attenuation parameter, liver stiffness measurement, and prevalence of MS compared to those with mild steatosis. They also had larger visceral fat area, subcutaneous fat area, and low density dorsal muscle area. In addition, their calorie intake was higher and time spent on recreation activities was shorter. Conclusion: NAFLD patients with moderate/severe steatosis, including those with normal BMI, had higher prevalence of MS and more fat in visceral, subcutaneous, and muscle compartments than those with mild steatosis. They also had more advanced liver disease. Strategies to decrease hepatic fat may benefit both liver and metabolic diseases. |
| first_indexed | 2024-03-12T19:18:04Z |
| format | Article |
| id | doaj.art-8d900cdf12b04f05852f2f16c03c2838 |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-03-12T19:18:04Z |
| publishDate | 2019-12-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-8d900cdf12b04f05852f2f16c03c28382023-08-02T05:22:52ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2019-12-013121585159710.1002/hep4.1435Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic SteatosisWei Zhang0Rui Huang1Yi Wang2Huiying Rao3Lai Wei4Grace L. Su5Anna S. Lok6Peking University Hepatology Institute Peking University People's Hospital Beijing ChinaPeking University Hepatology Institute Peking University People's Hospital Beijing ChinaDepartment of Radiology Peking University People's Hospital Beijing ChinaPeking University Hepatology Institute Peking University People's Hospital Beijing ChinaPeking University Hepatology Institute Peking University People's Hospital Beijing ChinaDivision of Gastroenterology and Hepatology University of Michigan Ann Arbor MIDivision of Gastroenterology and Hepatology University of Michigan Ann Arbor MISeveral drugs in development for nonalcoholic fatty liver disease (NAFLD) aim to decrease the amount of fat in the liver. We compared quantity and quality of fat in subcutaneous, visceral and muscle compartments, liver fibrosis, and prevalence of metabolic abnormalities between Chinese patients with moderate/severe hepatic steatosis versus those with mild hepatic steatosis. NAFLD patients were prospectively recruited from Peking University People's Hospital in Beijing, China. All patients had baseline body composition measurements using computed tomography and analytic morphomics, clinical evaluation, labs and Fibroscan® controlled attenuation parameter and liver stiffness measurement. Moderate/severe hepatic steatosis was defined as computed tomography liver attenuation of 40 Hounsfield units or less. Calorie intake and physical activity were based on self‐report. A total of 160 NAFLD patients were included (46% men, median age 47 years): 50% had normal body mass index (BMI), 24% were diabetic, and 56% had metabolic syndrome (MS). Fifty‐three (33%) had moderate/severe steatosis, of whom 19 (35.8%) had normal BMI, and the rest had mild steatosis. Patients who had moderate/severe steatosis had significantly higher BMI, waist circumference, aminotransferases, controlled attenuation parameter, liver stiffness measurement, and prevalence of MS compared to those with mild steatosis. They also had larger visceral fat area, subcutaneous fat area, and low density dorsal muscle area. In addition, their calorie intake was higher and time spent on recreation activities was shorter. Conclusion: NAFLD patients with moderate/severe steatosis, including those with normal BMI, had higher prevalence of MS and more fat in visceral, subcutaneous, and muscle compartments than those with mild steatosis. They also had more advanced liver disease. Strategies to decrease hepatic fat may benefit both liver and metabolic diseases.https://doi.org/10.1002/hep4.1435 |
| spellingShingle | Wei Zhang Rui Huang Yi Wang Huiying Rao Lai Wei Grace L. Su Anna S. Lok Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis Hepatology Communications |
| title | Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis |
| title_full | Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis |
| title_fullStr | Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis |
| title_full_unstemmed | Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis |
| title_short | Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis |
| title_sort | fat accumulation liver fibrosis and metabolic abnormalities in chinese patients with moderate severe versus mild hepatic steatosis |
| url | https://doi.org/10.1002/hep4.1435 |
| work_keys_str_mv | AT weizhang fataccumulationliverfibrosisandmetabolicabnormalitiesinchinesepatientswithmoderatesevereversusmildhepaticsteatosis AT ruihuang fataccumulationliverfibrosisandmetabolicabnormalitiesinchinesepatientswithmoderatesevereversusmildhepaticsteatosis AT yiwang fataccumulationliverfibrosisandmetabolicabnormalitiesinchinesepatientswithmoderatesevereversusmildhepaticsteatosis AT huiyingrao fataccumulationliverfibrosisandmetabolicabnormalitiesinchinesepatientswithmoderatesevereversusmildhepaticsteatosis AT laiwei fataccumulationliverfibrosisandmetabolicabnormalitiesinchinesepatientswithmoderatesevereversusmildhepaticsteatosis AT gracelsu fataccumulationliverfibrosisandmetabolicabnormalitiesinchinesepatientswithmoderatesevereversusmildhepaticsteatosis AT annaslok fataccumulationliverfibrosisandmetabolicabnormalitiesinchinesepatientswithmoderatesevereversusmildhepaticsteatosis |